US 12,465,569 B2
Microparticle formulations for intravenous therapy and methods for their manufacture and use
Haifa Shen, Bellaire, TX (US); Mauro Ferrari, Houston, TX (US); Zhenhua Hu, Houston, TX (US); and Guodong Zhang, Sugar Land, TX (US)
Assigned to The Methodist Hospital, Houston, TX (US)
Filed by The Methodist Hospital, Houston, TX (US)
Filed on Dec. 13, 2024, as Appl. No. 18/980,349.
Application 18/980,349 is a continuation of application No. PCT/US2023/033625, filed on Sep. 25, 2023.
Claims priority of provisional application 63/409,935, filed on Sep. 26, 2022.
Prior Publication US 2025/0108010 A1, Apr. 3, 2025
Int. Cl. A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/50 (2017.01); A61K 47/59 (2017.01); A61P 31/00 (2006.01)
CPC A61K 9/1652 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1641 (2013.01); A61K 9/1694 (2013.01); A61K 47/593 (2017.08)] 14 Claims
OG exemplary drawing
 
1. A formulation for intravenous injection comprising:
therapeutic microparticles, wherein the therapeutic microparticles are porous silicon microparticles containing a polymer of L-glutamic acid conjugated with doxorubicin, wherein the polymer has a weight average molecular weight of 70-80 kDa,
from about 0.80 weight percent to about 1.60 weight percent of sodium carboxymethyl cellulose based on a total weight of the formulation,
from about 0.12 weight percent to about 0.28 weight percent of poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) based on the total weight of the formulation,
from about 0.22 weight percent to about 0.78 weight percent of mannitol based on the total weight of the formulation, and
water.